Pembrolizumab for Early Triple-Negative Breast Cancer
Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plu...
Publications
3 shownTrastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
In this trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the p...
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer. In addition to nausea and myelosuppressi...
Frequent Co-Authors
Researcher Info
- h-index
- 3
- Publications
- 3
- Citations
- 6,667
- Institution
- Samsung Medical Center
External Links
Identifiers
- ORCID
- 0000-0003-4156-9212
Impact Metrics
h-index
3
h-index: Number of publications with at least h citations each.